TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8536521
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of CCK (24 pmol/kg/hr)
Study: 6990334
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with antimicrobials (cefamandole) starting preoperatively and continuing for 4 days
Study: 6990334
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (treatment only if infection was apparent)
Study: 23728174
Drug: Exenatide (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (subcutaneous injection for 12 months)
Study: 12788888
Drug: 1 implant
Normalized name: LEUPROLIDE ACETATE 72 MILLIGRAM In 1 IMPLANT SUBCUTANEOUS IMPLANT [Viadur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 implant of MENT (400 microg/d x implant)
Study: 12788888
Drug: 2 implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 implants of MENT (400 microg/d x implant)
Study: 10825322
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl infusion at 1.5 ng/mL
Study: 10825322
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl infusion at 3.0 ng/mL
Study: 10825322
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl infusion at 4.5 ng/mL
Study: 6363158
Drug: Diproderm cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diproderm cream 0.05%, applied twice a day
Study: 6363158
Drug: Diproderm cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diproderm cream 0.05%, applied once a day
Study: 22795613
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine alone
Study: 22795613
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine and IV oxycodone (0.75 mg each)
Study: 22795613
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine plus IV oxycodone (0.5 mg/0.5 mg) via PCA
Study: 22795613
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg IV morphine alone via PCA
Study: 17519714
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml 0.75% ropivacaine
Study: 17519714
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml 2% lidocaine
Study: 8451009
Drug: Aspartame 600
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame 600 mg
Study: 8451009
Drug: Aspartame 1200
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame 1200 mg
Study: 31317843
Drug: Radically Open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radically Open Dialectical Behaviour Therapy (RO DBT) plus Treatment as Usual (TAU)
Study: 31317843
Drug: Radically Open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radically Open Dialectical Behaviour Therapy (RO DBT)
Study: 31127381
Drug: Aflibercept injections
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept injections alone (Group A)
Study: 31127381
Drug: Aflibercept injections
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept injections followed by micropulsed laser (Group B)
Study: 24706354
Drug: Cognitive-behavioral conjoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral conjoint therapy for PTSD
Study: 21823174
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music intervention using percussion instruments with familiar music, 30-min sessions, twice weekly for 6 weeks
Study: 15366327
Drug: Isosorbide-5-mononitrate prolonged-release
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate prolonged-release tablet formulation (60 mg)
Study: 10995136
Drug: Continuous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous propofol administration
Study: 1637600
Drug: Isoflurane administration
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane administration
Study: 23920422
Drug: MK-0249 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0249 (5, 8, 10, or 12 mg)
Study: 21995156
Drug: Topical lipohydroperoxides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lipohydroperoxides and glycyrrhetic acid for three days (n = 50)
Study: 21995156
Drug: Vaginal antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal antibacterial metronidazole (500 mg) or antimycotic econazole (150 mg) for six days (n = 50)
Study: 21995156
Drug: Topical lipohydroperoxides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lipohydroperoxides and glycyrrhetic acid
Study: 19337019
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IG) + repaglinide
Study: 19337019
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IG) + acarbose
Study: 15475831
Drug: losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan (50 mg/d)
Study: 14999200
Drug: captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (50 mg 3 times/d)
Study: 10705305
Drug: r‐IL‐2 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐IL‐2 therapy (12 M IU/m2/day continuous infusion on day 1‐5, 15‐17, 29‐31, 43‐45 and 57‐59)
Study: 10705305
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no r‐IL‐2 therapy)
Study: 9158540
Drug: Frequent quizzes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent quizzes administered at the beginning of each class (Quiz Group - QG)
Study: 1540458
Drug: Three cotton
Normalized name: Cotton
DrugBank: Cotton (DB10707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cotton swabs soaked in 4% lignocaine solution
Study: 25451347
Drug: Arformoterol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arformoterol (15 μg bid)
Study: 22342501
Drug: Intanza(®) 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intanza(®) 15 μg intradermal vaccine
Study: 22342501
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) Vaxigrip(®) vaccine
Study: 18541078
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 ml) plus ondansetron 4 mg (2 ml)
Study: 18541078
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg (2 ml) and normal saline (2 ml)
Study: 16183940
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for thromboembolic disease
Study: 14569216
Drug: Nonsurgical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatments for sciatica
Study: 8565536
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (2 g, 8 mmol)
Study: 1759835
Drug: Org 10172
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 10172 (intravenous bolus injection of 3,250 anti‐Xa units) + cloxacillin (500 mg orally four times daily for 3 days)
Study: 1759835
Drug: Org 10172
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 10172 (intravenous bolus injection of 3,250 anti‐Xa units) + ticarcillin (4,000 mg intravenously four times daily for 2 days)
Study: 7058755
Drug: Sulfinpyrazone (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfinpyrazone (800 mg/day)
Study: 21303190
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (twice weekly for 3 weeks, total six sessions)
Study: 21303190
Drug: Observation (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (routine care with weekly visits)
Study: 11942472
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in plasma 8-iso-prostaglandin F2alpha (SD = 8.88 ng/L)
Study: 11942472
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in apolipoprotein B (SD = 0.27 g/L)
Study: 2679288
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate and fluorouracil (M-F) followed by leucovorin in Protocol B-13
Study: 2679288
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg twice daily) in Protocol B-14
Study: 785426
Drug: Aerosol vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol vaccine
Study: 785426
Drug: Whole-virion vaccine
Normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virion vaccine
Study: 785426
Drug: Tween-ether ‘split’
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tween-ether ‘split’ vaccine
Study: 785426
Drug: Aerosol vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol vaccine (field trial)
Study: 785426
Drug: Whole-virion vaccine
Normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virion vaccine (field trial)
Study: 29411724
Drug: LACB-7 (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: LACB-7 (7-day quadruple therapy)
Study: 29411724
Drug: LACB-14 (14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: LACB-14 (14-day quadruple therapy)
Study: 20846715
Drug: Thalidomide 200mg
Normalized name: THALIDOMIDE 200MG CAP
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 200mg daily (escalated to 400mg)
Study: 20846715
Drug: Tamoxifen 20mg
Normalized name: tamoxifen 20 MG
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20mg orally twice daily
Study: 31959397
Drug: Implant-supported cantilever
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported cantilever fixed partial dentures (ICFPDs)
Study: 31959397
Drug: Implant-supported conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported conventional fixed partial dentures (IFF)
Study: 27492975
Drug: Orafti® Inulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orafti® Inulin (3 x 4g daily for 4 weeks)
Study: 11566619
Drug: Onercept 50
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 50 mg IV
Study: 11566619
Drug: Onercept 150
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 150 mg IV
Study: 11566619
Drug: Onercept 50
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 50 mg SC (single injection)
Study: 11566619
Drug: Onercept 50
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 50 mg SC (six repeated injections)
Study: 11566619
Drug: Onercept (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept (various doses)
Study: 9470156
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVGG) at a dosage of 0.5 g/kg (range 0.25 to 0.73 g/kg) administered after 10.4 +/- 6.6 days of prednisone therapy
Study: 31722536
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy alone
Study: 30204730
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment guided by visual acuity stabilization criteria (Group I)
Study: 30204730
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment guided by disease activity (Group II)
Study: 30204730
Drug: Verteporfin photodynamic
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin photodynamic therapy (Group III)
Study: 30204730
Drug: Ranibizumab injections
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab injections (Groups I/II)
Study: 28010989
Drug: Mesh augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesh augmentation
Study: 28010989
Drug: Graft augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graft augmentation
Study: 25517761
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with 3 × 5 min occlusion
Study: 21192150
Drug: Citalopram or
Normalized name: citalopram Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram or Fluoxetine (dose increase at week 6)
Study: 21192150
Drug: SSRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI plus cognitive behavior therapy
Study: 21192150
Drug: Venlafaxine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine plus cognitive behavior therapy
Study: 17123235
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg (GRA1) + 8 mg dexamethasone
Study: 17123235
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg (GRA3) + 8 mg dexamethasone
Study: 17123235
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg (OND8) + 8 mg dexamethasone
Study: 9482177
Drug: Ebselen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebselen (150 mg, twice a day for 2 weeks)
Study: 8059693
Drug: Volume loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume loading (mean 400 ml saline solution)
Study: 3143264
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glyburide
Study: 29121326
Drug: Increased FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased FSH dose (225/450 IU/day)
Study: 29121326
Drug: Standard FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard FSH dose (150 IU/day)
Study: 22079215
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral therapy (CBT)
Study: 23669884
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control treatment (MoodGYM)
Study: 15273918
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy in hypogonadal patients
Study: 15273918
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy of calcium and vitamin D
Study: 6752712
Drug: Oxprenolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (40 mg twice daily)
Study: 29089066
Drug: Lotilaner (Credelio™)
Normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner (Credelio™) at a dose of 20 mg/kg, administered orally 30 minutes after feeding.
Study: 21835280
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg dalcetrapib daily for 24 months
Study: 21835280
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 24 months
Study: 16703780
Drug: 4.5%/8.5% benzoyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products along with oral doxycycline
Study: 16703780
Drug: 4.5%/8.5% benzoyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products along with oral minocycline
Study: 14654718
Drug: GH 0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 0.23 mg/kg/week (group A)
Study: 14654718
Drug: GH 0.46
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 0.46 mg/kg/week (group B)
Study: 14654718
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (both groups)
Study: 9671870
Drug: Levofloxacin 250
Normalized name: levofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 250 mg once daily
Study: 1316058
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg once daily
Study: 7836549
Drug: Tacrine (Cognex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (Cognex, THA) administered after an 8-hour overnight fast
Study: 7836549
Drug: Tacrine (Cognex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (Cognex, THA) administered 1 hour before a standard breakfast
Study: 7836549
Drug: Tacrine (Cognex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (Cognex, THA) administered 15 minutes after beginning a standard breakfast
Study: 7836549
Drug: Tacrine (Cognex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (Cognex, THA) administered 2 hours after completion of a standard breakfast
Study: 3046277
Drug: Sotalol, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol, 160 mg twice daily
Study: 3046277
Drug: Atenolol, 50
Normalized name: Atenolol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 50 mg twice daily
Study: 3046277
Drug: Intravenous sotalol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sotalol, 100 mg
Study: 3046277
Drug: Intravenous atenolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous atenolol, 10 mg
Study: 23650294
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% gel
Study: 21068676
Drug: Creatine (PEG-creatine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (PEG-creatine, 5 g·d)
Study: 21068676
Drug: Placebo (maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin powder, 5 g·d)
Study: 12675866
Drug: Dual blockade
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual blockade of the renin-angiotensin system (RAS) with irbesartan 300 mg (once daily) and enalapril 40 mg (once daily)
Study: 12675866
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors + placebo
Study: 10963287
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) plus medical treatment
Study: 9151611
Drug: One-stage IMZ
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage IMZ implant placement
Study: 9151611
Drug: Two-stage IMZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage IMZ implant placement
Study: 8403954
Drug: Topical antibiotics
Normalized name: Tetracycline and derivatives, topical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotics (tobramycin, polymyxin E, amphotericin B, vancomycin)
Study: 8403954
Drug: Placebo (suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (suspension of fluid and paste without antibiotics)
Study: 2885854
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg per day)
Study: 2885854
Drug: Terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (120 mg per day)
Study: 18211927
Drug: Deep Sclerectomy
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Sclerectomy with Collagen Implant (DSCI)
Study: 8626359
Drug: Nefazodone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (mean dose at endpoint = 379 mg/day)
Study: 1336527
Drug: Captopril at
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril at 25 mg twice a day
Study: 1336527
Drug: Atenolol at
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol at 50 mg once a day
Study: 30972581
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or group cognitive-behavioral therapy for 14 weeks
Study: 18698012
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin (162 mg)
Study: 18698012
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl salicylate (5 g of 30% preparation)
Study: 16385104
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment strategies for migraine
Study: 16385104
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment strategies for migraine
Study: 12450883
Drug: High-protein, high-methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein, high-methionine diet (HP: 22% of total energy, 2.7 g methionine/d; n = 25)
Study: 12450883
Drug: Low-protein, low-methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein, low-methionine diet (LP: 12% of total energy, 1.4 g methionine/d; n = 25)
Study: 10369491
Drug: Iron (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (14 mg/d) and 60 mg/d vitamin C (Group A)
Study: 10369491
Drug: Iron (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (14 mg/d) and 260 mg/d vitamin C (Group B)
Study: 7575897
Drug: Infusions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions of 250 ml 10% HES 200/0.5
Study: 7575897
Drug: Infusions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions of 500 ml 10% HES 200/0.5